TY  - JOUR
AU  - Luke, Jason J
AU  - Ascierto, Paolo A
AU  - Khattak, Muhammad A
AU  - Rutkowski, Piotr
AU  - Del Vecchio, Michele
AU  - Spagnolo, Francesco
AU  - Mackiewicz, Jacek
AU  - Merino, Luis de la Cruz
AU  - Chiarion-Sileni, Vanna
AU  - Kirkwood, John M
AU  - Robert, Caroline
AU  - Schadendorf, Dirk
AU  - de Galitiis, Federica
AU  - Carlino, Matteo S
AU  - Dummer, Reinhard
AU  - Mohr, Peter
AU  - Odeleye-Ajakaye, Amos
AU  - Fukunaga-Kalabis, Mizuho
AU  - Krepler, Clemens
AU  - Eggermont, Alexander M M
AU  - Long, Georgina V
TI  - Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
JO  - European journal of cancer
VL  - 220
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-00757
SP  - 115381
PY  - 2025
AB  - Adjuvant pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB/IIC melanoma in KEYNOTE-716. Results of a post hoc 4-year analysis are reported, including progression/recurrence-free survival 2 (PRFS2).Patients were randomly assigned 1:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks (part 1). RFS was the primary end point; DMFS was secondary. Patients with recurrence following placebo or 17 cycles of pembrolizumab could cross over to or be rechallenged with pembrolizumab (part 2).Median follow-up (n = 976) was 52.8 months (range, 39.4-64.8). RFS (HR, 0.62 [95 
KW  - Adjuvant therapy (Other)
KW  - Immune checkpoint inhibitors (Other)
KW  - Melanoma (Other)
KW  - Pembrolizumab (Other)
KW  - Programmed cell death protein 1 (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40198940
DO  - DOI:10.1016/j.ejca.2025.115381
UR  - https://inrepo02.dkfz.de/record/300307
ER  -